Impact of changes in diabetes screening guidelines on testing eligibility and potential yield among adults without diagnosed diabetes in the United States
Authors' conclusion
An additional 12-14 million US adults are eligible for diabetes screening. USPSTF 2021 criteria provide balanced sensitivity and specificity while ADA 2022 criteria maximize sensitivity. Glucose testing does not align with guidelines and disparities remain.
Study context
- Population
- Non-pregnant US adults without diagnosed diabetes, NHANES 2013–2018
- Participants
- 6,007 adults
- Exposure
- USPSTF 2015 and 2021 vs ADA 2003 and 2022 diabetes screening guidelines
- Outcome
- US adults eligible for glucose testing
- Follow-up
- 2013-2018
Methodological detailsNHANES 2013-2018
- NHANES 2013-2018
Main finding
As reported in the abstract
USPSTF 2015
76.7 million
USPSTF 2021
90.4 million
ADA 2003
157.7 million
ADA 2022
169.5 million
Observational data: associations, not effects.
Further findings
Performance for prediabetes or undiagnosed diabetes
- ADA recommendations sensitivity (range)
- 91.0 % to 100.0 %
- ADA recommendations specificity (range)
- 18.3 % to 35.3 %
- USPSTF recommendations sensitivity
- 51.9 % to 66.6 %
- USPSTF recommendations specificity
- 56.6 % to 74.5 %
Reported glucose testing within past 3 years
- Adults reporting glucose testing, on average
- 52 %
- Lower likelihood among younger adults, men, Hispanic adults, those with less than high school completion, in poverty, or without health insurance or usual place of care
Original publication
Impact of changes in diabetes screening guidelines on testing eligibility and potential yield among adults without diagnosed diabetes in the United States. Diabetes Res Clin Pract. Published 11 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →